Vijay Raj Ramakrishnan

8592149, Nov 26, 2013

Apr 27, 2007

12/298661

Vijay Ramakrishnan - Palo Alto CA, US

PIKAMAB, Inc. - Palo Alto CA

C12Q 1/68
G01N 33/50

435 61, 702 19, 702 20

Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcγRIIA polymorphism, or a FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and a FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism.

20060147997, Jul 6, 2006

Nov 30, 2005

11/290143

Vijay Ramakrishnan - Los Altos Hills CA, US

Virosys Pharmaceuticals, Inc. - Los Altos Hills CA

C40B 40/10
A61K 39/02

435007100, 424234100

The present invention relates to methods of making and using chimeric antibody molecules comprised of at least two domains, namely R, and I, linked by a flexible peptide linker.

20120030144, Feb 2, 2012

Nov 7, 2008

12/742056

Vijay Ramakrishnan - Menlo Park CA, US

PIKAMAB, INC. - Menlo Park CA

G06Q 30/00

705500

The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective.

20120039871, Feb 16, 2012

Nov 7, 2008

12/742066

Vijay Ramakrishnan - Menlo Park CA, US

PIKAMAB, INC. - Menlo Park CA

A61K 39/395
A61P 37/06
A61P 31/00
A61P 35/00

4241331, 4241301, 4241731, 4241531

Methods and materials are provided for selecting and/or treating a subject based on a FcγRIIA polymorphism, or a FcγRIIB polymorphism, or both an FcγRIIA polymorphism and a FcγRIIB polymorphism, for treatment with a therapy including an antibody therapy such as rituximab. Methods are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIB polymorphism, or both the FcγRIIA polymorphism and the FcγRIIB polymorphism.

20210225475, Jul 22, 2021

Mar 16, 2021

17/202453

- MENLO PARK CA, US
Vijay Ramakrishnan - Palo Alto CA, US

G16H 20/10
G06Q 40/08
G16H 10/60
G16H 50/70

The present disclosure provides methods, processes, reagents and kits for novel healthcare delivery, treatment and payment, particularly for achieving better economic outcomes in patients treated with specialty drugs. Methods, processes, and kits provide a number of uses, including, for providing assurance, both efficacy and financial, theragnostic-guidance, for providing therapeutic appropriateness, therapeutic guidance, therapeutic effectiveness, and selection of alternative therapeutic strategies, and providing product differentiation and presumably market enrichment for a specialty drug, for authorizing payment and delivering the drug directly from a pharmaceutical company to a patient or her specialty physician through a novel healthcare delivery platform. Medical records and databases using these strategies are also provided.

20190378597, Dec 12, 2019

Nov 23, 2016

15/360799

Vijay Ramakrishnan - Palo Alto CA, US

G16H 20/10
G16H 50/70
G16H 10/60
G06Q 40/08

The present disclosure provides methods, processes, reagents and kits for novel healthcare delivery, treatment and payment, particularly for achieving better economic outcomes in patients treated with specialty drugs. Methods, processes, and kits provide a number of uses, including, for providing assurance, both efficacy and financial, theragnostic-guidance, for providing therapeutic appropriateness, therapeutic guidance, therapeutic effectiveness, and selection of alternative therapeutic strategies, and providing product differentiation and presumably market enrichment for a specialty drug, for authorizing payment and delivering the drug directly from a pharmaceutical company to a patient or her specialty physician through a novel healthcare delivery platform. Medical records and databases using these strategies are also provided.

20170068863, Mar 9, 2017

Aug 30, 2016

15/252150

- San Diego CA, US
Abhikrant Sharma - Hyderabad, IN
Vijay Ramakrishnan - Redwood City CA, US
Rasjinder Singh - San Diego CA, US

G06K 9/00
G06K 9/32
G06T 7/00
G06K 9/66
G06K 9/34

Occupancy in a vehicle is determined by maintaining a set of occupant regions detected in a video. An occupant region can be a bounding box around a face, and/or an occupied seat that does not overlap any bounding box. A count, specific to an occupant region, is set to zero when an overlap between the occupant region in a current frame in the video and a previous frame in the video, satisfies a first predetermined condition. When the overlap does not satisfy the first predetermined condition, the count which is specific to the occupant region is incremented and checked against a threshold in a second predetermined condition. When the count exceeds the threshold, that occupant region is removed from the set of occupant regions. The just-described operations are repeated, with additional occupant regions. A count of occupant regions currently in the set may be displayed or transmitted to a server.

20160026766, Jan 28, 2016

Oct 7, 2015

14/877822

- Menlo Park CA, US
Vijay Ramakrishnan - Menlo Park CA, US

G06F 19/00
G06Q 50/22
C12Q 1/68
G06Q 30/02

The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective.